DID YOU KNOW? Medtronic CGM has an +80% approval rate through insurance.**

By submitting this form you are consenting to and confirm the following:

  • That Medtronic can communicate with you regarding our diabetes products by telephone, fax, mail and/or e-mail.
  • That Medtronic stores information, including personal health information, on systems located outside of Canada.
  • That you have read and are aware of our privacy policy.
  • That you grant Medtronic of Canada permission to send you updates on diabetes and diabetes technology.
  • You may revoke this permission at any time by emailing medtronicdiabetescc@medtronic.com
  • Medtronic respects the confidentiality of personal information. We assure you we will not share your personal information, except as otherwise noted in our privacy policy.


If you've been considering a change, this could be a great time to make the move to our latest technology. Fill out the form to learn more.


Individual results may vary. The MiniMed 670G is indicated for people living with type 1 diabetes, seven years of age and older.

*90% reduction in injections assumes four injections per day for 30 days and one infusion set change every two to three days. **Data on file. 2019.

1. Mueckler, JR et al. Real-World Assessment of Former MDI Patients’ Experience on the Medtronic MiniMed™ 670G Hybrid Closed-Loop System (n=47). Poster presented at the 11th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD); 2017 February 14-17, Vienna, Austria